Traws Pharma (TRAW) stock surged on Tuesday after the clinical-stage biopharmaceutical company revealed results from a rigosertib study as a treatment for patients with RDEB SCC. The results posted by the company include an overall response rate of 80%, with a complete response rate of 50%.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Traws Pharma interim CEO Iain Dukes said, “Rigosertib is available for further development and commercialization, and we are committed to finding an appropriate partner to advance this important medicine to approval.”
TRAW stock was up 57.04% on Tuesday but remains down 84.01% year-to-date. The stock has also fallen 90.44% over the past 12 months.
Is Traws Pharma Stock a Buy, Sell, or Hold?
Wall Street’s coverage of Traws Pharma is lacking. However, TipRanks’ AI analyst, Spark, rates the stock as Underperform (28) with no price target. The rating comes from “significant financial challenges and bearish technical indicators.”
